{"nctId":"NCT00149890","briefTitle":"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","startDateStruct":{"date":"2004-03"},"conditions":["Liver Transplantation","Infection"],"count":77,"armGroups":[{"label":"With Intraoperative Steroids","type":"EXPERIMENTAL","interventionNames":["Drug: Basiliximab","Drug: Cyclosporine/cyclosporine microemulsion","Drug: Steroid"]},{"label":"Without Intraoperative Steroids","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Basiliximab","Drug: Cyclosporine/cyclosporine microemulsion","Drug: Steroid"]}],"interventions":[{"name":"Basiliximab","otherNames":["Simulect®"]},{"name":"Cyclosporine/cyclosporine microemulsion","otherNames":["Sandimmun®/Sandimmun® Optoral"]},{"name":"Steroid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pediatric patients undergoing primary orthotopic liver transplantation (whole organ or split liver or reduced size)\n* Cadaveric or living donor (related or unrelated)\n\nExclusion Criteria:\n\n* Patients who are recipients of multiple solid organ transplants and/or who have previously received transplanted organs\n* If cold ischemia time of the transplanted organ is \\>12 hours\n* Auxiliary liver transplant recipients\n* Fulminant hepatic failure\n* Autoimmune hepatitis\n* Primary sclerosing cholangitis\n* Severe acute systemic infections\n* Hepatitis B surface antigen/HCV/HIV positive\n* Known contraindication to intravenous (i.v.) or per os (orally) (p.o.) cyclosporine or corticoids\n* Non-ability to comply with the protocol\n* Relevant abnormal physical or laboratory findings within 2 weeks of inclusion\n* Relevant severe allergy, hypersensitivity to basiliximab or similar drugs\n* History/presence of relevant malignancy\n* Pregnancy/breastfeeding\n* Use of any investigational or immunomodulatory/immunosuppressive drug within 4 weeks prior to transplantation.","healthyVolunteers":false,"sex":"ALL","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation","description":"Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months","description":"At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months","description":"To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation","description":"Graft loss is defined as being listed for a re-transplantation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bacterial, Viral and Fungal Infections During Six Months","description":"To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Time of Onset of a First Biopsy Proven Acute Rejection","description":"Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension\n\n.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment Failure Within Three and Six Months","description":"To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"4.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":null},{"groupId":"OG001","value":"7.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":null},{"groupId":"OG001","value":"5.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"4.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":null},{"groupId":"OG001","value":"7.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":null},{"groupId":"OG001","value":"5.26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":39},"commonTop":["Hypertension","Pyrexia","Pleural effusion","Flatulence","Hypomagnesaemia"]}}}